ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LEN
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection
Trial Timeline
Oct 9, 2024 → Aug 1, 2030
NCT ID
NCT06630286About ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LEN
ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LEN is a phase 3 stage product being developed by Merck for HIV-1-infection. The current trial status is active. This product is registered under clinical trial identifier NCT06630286. Target conditions include HIV-1-infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06630286 | Phase 3 | Active |
Competing Products
20 competing products in HIV-1-infection